EA201600506A1 - КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ - Google Patents

КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ

Info

Publication number
EA201600506A1
EA201600506A1 EA201600506A EA201600506A EA201600506A1 EA 201600506 A1 EA201600506 A1 EA 201600506A1 EA 201600506 A EA201600506 A EA 201600506A EA 201600506 A EA201600506 A EA 201600506A EA 201600506 A1 EA201600506 A1 EA 201600506A1
Authority
EA
Eurasian Patent Office
Prior art keywords
preparation
cyclopropylbenzyl
medicines
cyano
benzene
Prior art date
Application number
EA201600506A
Other languages
English (en)
Russian (ru)
Inventor
Маттиас Экхардт
Таня БУТЦ
Франк Химмельсбах
Ханс-Юрген Мартин
Original Assignee
Бёрингер Ингельхайм Ветмедика Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Ветмедика Гмбх filed Critical Бёрингер Ингельхайм Ветмедика Гмбх
Publication of EA201600506A1 publication Critical patent/EA201600506A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EA201600506A 2012-07-26 2013-07-25 КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ EA201600506A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12177944 2012-07-26

Publications (1)

Publication Number Publication Date
EA201600506A1 true EA201600506A1 (ru) 2017-03-31

Family

ID=48874313

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201600506A EA201600506A1 (ru) 2012-07-26 2013-07-25 КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
EA201500038A EA025438B1 (ru) 2012-07-26 2013-07-25 КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201500038A EA025438B1 (ru) 2012-07-26 2013-07-25 КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ

Country Status (23)

Country Link
US (1) US9145434B2 (cg-RX-API-DMAC7.html)
EP (3) EP2877460B1 (cg-RX-API-DMAC7.html)
JP (2) JP6538556B2 (cg-RX-API-DMAC7.html)
CN (2) CN104470908A (cg-RX-API-DMAC7.html)
AR (1) AR091908A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013294947B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015001327B1 (cg-RX-API-DMAC7.html)
CA (1) CA2878698C (cg-RX-API-DMAC7.html)
DK (2) DK3351539T3 (cg-RX-API-DMAC7.html)
EA (2) EA201600506A1 (cg-RX-API-DMAC7.html)
ES (2) ES2937665T3 (cg-RX-API-DMAC7.html)
FI (1) FI3351539T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20230081T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061450T2 (cg-RX-API-DMAC7.html)
LT (1) LT3351539T (cg-RX-API-DMAC7.html)
MX (1) MX357906B (cg-RX-API-DMAC7.html)
PL (2) PL2877460T3 (cg-RX-API-DMAC7.html)
PT (2) PT2877460T (cg-RX-API-DMAC7.html)
RS (1) RS63881B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201500574QA (cg-RX-API-DMAC7.html)
SI (2) SI2877460T1 (cg-RX-API-DMAC7.html)
TW (1) TW201418275A (cg-RX-API-DMAC7.html)
WO (1) WO2014016381A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
ES2859905T3 (es) 2013-12-17 2021-10-04 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales felinos
US10603300B2 (en) * 2014-01-23 2020-03-31 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
ES2811261T3 (es) * 2014-04-01 2021-03-11 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabólicos en animales equinos
CN103965020B (zh) * 2014-05-06 2015-09-09 启东东岳药业有限公司 制备5-碘-2-溴苄醇的方法
ES2991763T3 (es) 2014-09-25 2024-12-04 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de combinación de inhibidores de SGLT2 y agonistas de dopamina para la prevención de trastornos metabólicos en animales equinos
PT3202772T (pt) * 2014-09-30 2020-11-20 Jiangsu Hengrui Medicine Co Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2
CZ2015110A3 (cs) * 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
CN107995862B8 (zh) 2015-08-27 2021-12-03 勃林格殷格翰维特梅迪卡有限公司 包含sglt-2抑制剂之液态药物组合物
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
KR102226465B1 (ko) * 2016-05-28 2021-03-11 하이난 수안주 파마 코포레이션 리미티드 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형
CN111511725B (zh) * 2017-12-19 2024-04-09 勃林格殷格翰维特梅迪卡有限公司 1-氰基-2-(4-环丙基-苄基)-4-(β-D-吡喃葡萄糖-1-基)-苯、L-脯氨酸和水的1:1:1共晶体的合成
UY38969A (es) 2019-11-28 2021-05-31 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
CN118615450A (zh) 2020-02-17 2024-09-10 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
CA3223537A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
EP4376819A1 (en) 2021-07-28 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
JP2024525981A (ja) 2021-07-28 2024-07-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ヒト以外の哺乳動物における腎疾患の予防及び/又は治療のためのsglt-2阻害剤の使用
JP2025516857A (ja) 2022-05-25 2025-05-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Sglt-2阻害薬を含む水性医薬組成物
AU2024233233A1 (en) 2023-03-06 2025-09-11 Boehringer Ingelheim Vetmedica Gmbh Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
WO2024223388A1 (en) 2023-04-24 2024-10-31 Boehringer Ingelheim Vetmedica Gmbh Crystalline complexes between velagliflozin and selected co-crystal forming agents, methods for their preparation and the use thereof for preparing medicaments
TW202508593A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258141T3 (es) 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
EP1581543A4 (en) * 2003-01-03 2008-03-19 Bristol Myers Squibb Co METHODS FOR PRODUCING SGLT2 GLYCOSIS C-ARYL INHIBITORS
CN103435581B (zh) * 2004-03-16 2015-08-19 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
ATE491700T1 (de) * 2005-09-08 2011-01-15 Boehringer Ingelheim Int KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-
ATE517099T1 (de) * 2006-02-15 2011-08-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
EP2147008A2 (en) * 2007-05-18 2010-01-27 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
CN103319445B (zh) * 2007-12-27 2016-01-20 阿斯利康公司 Sglt2抑制剂的晶体结构及其制备方法
CN102177147A (zh) * 2008-08-22 2011-09-07 泰拉科斯有限公司 制备sglt2抑制剂的方法
AU2009286380B2 (en) 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
US20100167988A1 (en) 2008-10-22 2010-07-01 Auspex Pharmaceuticals, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych

Also Published As

Publication number Publication date
WO2014016381A1 (en) 2014-01-30
ES2937665T3 (es) 2023-03-30
US20140031540A1 (en) 2014-01-30
US9145434B2 (en) 2015-09-29
JP2015522644A (ja) 2015-08-06
CN108774200A (zh) 2018-11-09
CA2878698A1 (en) 2014-01-30
MX2015000962A (es) 2015-04-16
MX357906B (es) 2018-07-30
RS63881B1 (sr) 2023-02-28
AR091908A1 (es) 2015-03-11
AU2013294947A1 (en) 2015-01-22
SI2877460T1 (sl) 2018-12-31
LT3351539T (lt) 2023-02-10
BR112015001327A2 (pt) 2017-07-04
DK3351539T3 (da) 2023-01-30
CA2878698C (en) 2021-03-23
PL3351539T3 (pl) 2023-03-06
JP2018135384A (ja) 2018-08-30
FI3351539T3 (fi) 2023-02-19
HRP20181972T1 (hr) 2019-01-25
EA201500038A1 (ru) 2015-07-30
ES2694675T3 (es) 2018-12-26
PT3351539T (pt) 2023-01-17
EA025438B1 (ru) 2016-12-30
TW201418275A (zh) 2014-05-16
PT2877460T (pt) 2018-12-19
EP3351539B1 (en) 2022-11-09
PL2877460T3 (pl) 2019-04-30
BR112015001327B1 (pt) 2022-08-16
AU2013294947B2 (en) 2017-03-30
EP3351539A1 (en) 2018-07-25
EP4166548A1 (en) 2023-04-19
HRP20230081T1 (hr) 2023-03-17
SG11201500574QA (en) 2015-02-27
JP6538556B2 (ja) 2019-07-03
SI3351539T1 (sl) 2023-03-31
EP2877460B1 (en) 2018-09-12
DK2877460T3 (en) 2019-01-07
HUE061450T2 (hu) 2023-07-28
EP2877460A1 (en) 2015-06-03
CN104470908A (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
EA201600506A1 (ru) КРИСТАЛЛИЧЕСКИЙ КОМПЛЕКС 1-ЦИАНО-2-(4-ЦИКЛОПРОПИЛБЕНЗИЛ)-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)БЕНЗОЛА, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201300388A1 (ru) Соединения замещенного бензамида
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA202190619A1 (ru) Противовирусные соединения
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201500207A1 (ru) Гетероароматические соединения в качестве ингибиторов втк
EA201400753A1 (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
EA201400579A1 (ru) Антитела к il-36r
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
BR112013021134A2 (pt) moduladores e métodos de uso
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201591527A1 (ru) Новые производные пиридина
EA201491339A1 (ru) Замещенные аннеллированные пиримидины и триазины и их применение
EA201591064A1 (ru) Новые производные пиридина
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
EA201591624A1 (ru) Новые производные пиразола